Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects.

Summary Background Although there has been an intense debate whether concomitant use of proton-pump inhibitors (PPIs) attenuates the antiplatelet effects of thienopyridine derivatives, the drug–drug interaction remains unclear in Japanese patients with coronary artery disease. Methods and results Platelet function test was performed in 461 patients who were scheduled for or had undergone stent implantation, treated with 100 mg/day of aspirin and a thienopyridine (200 mg/day of ticlopidine or 75 mg/day of clopidogrel) for at least 14 days. Adenosine diphosphate-induced platelet aggregation was evaluated with screen filtration pressure method, and the upper quartile of high platelet reactivity was defined as high on-treatment platelet reactivity (HPR). PPI use was at physician's discretion. Patients taking a thienopyridine plus a PPI ( n  = 166) were older and had a higher incidence of acute coronary syndromes on admission compared with patients taking a thienopyridine without a PPI ( n  = 295). The rate of HPR was higher in patients taking a thienopyridine plus a PPI than in patients taking a thienopyridine without a PPI (31% vs 21%, p  = 0.01). On multivariate logistic regression analysis, independent predictors of HPR were concomitant PPI use [odds ratio (OR): 1.66, 95% confidence interval (CI): 1.03–2.68], diabetes mellitus (OR: 1.76, CI: 1.11–2.81), and calcium channel blockers use (OR: 1.93, CI: 1.18–3.18). However, there was no significant difference in the rate of extremely high platelet reactivity [58 patients (12.5%) with PATI  Conclusion HPR was frequently observed in Japanese patients treated with thienopyridines plus PPIs compared to those without PPIs. Further prospective studies are needed to estimate the risk of adverse cardiovascular events associated with concomitant use of PPIs and thienopyridines.